Skip to main content
Premium Trial:

Request an Annual Quote

NHGRI Starts Phase II of Long-Range Planning

NEW YORK (GenomeWeb News) – The National Human Genome Research Institute has started the second phase of its long-term planning process, and has called on the research community and interested parties to comment on recent updates it has made to a series of white papers it released at the end of last year.

The goal of the four white papers was to ask a series of questions in different areas about where genomics can, and should go in the future. The goal of this phase of the process is to begin discussing answers for the many questions the papers raised.

The paper topics include two focused on applications for genomics in clinical problems: one is about diagnostics, preventive medicine, and pharmacogenomics, and the second asks questions about therapeutics.

Another paper focuses entirely on the future of genome sequencing (how to target potential sequencing targets, for example), and another looks at genomics education and community engagement.

NHGRI held an initial public comment phase on the papers that ended in February, which was followed by revisions to its list of genomics-focused questions based on those comments.

The latest phase is a comment period that will last until June 30.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.